INBX 250117 50.00P (INBX250117P50000) Stock Options, News & Quotes

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

INBX250117P50000

Watchlist

0.00
0.000.00%

15min DelayClose Jan 22 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Inhibrx Biosciences Analyst Ratings
BenzingaJan 22 09:45 ET · Ratings
Inhibrx Prospective Colorectal Cancer Treatment Shows Encouraging Results, Trial Expansion Planned
MT NewswiresJan 21 17:48 ET
Inhibrx Biosciences Reports Promising Trial Results for INBRX-109
TipRanksJan 21 17:29 ET
Express News | Inhibrx Biosciences Inc - Phase 1 Trial Shows 1 Complete Response, 3 Partial Responses, 6 Stable Disease Cases
ReutersJan 21 17:02 ET
Express News | Inhibrx Biosciences Announces Preliminary Data From the Phase 1 Trial of Ozekibart (Inbrx-109) for the Treatment of Colorectal Cancer
ReutersJan 21 17:01 ET
Inhibrx Biosciences Announces Preliminary Data From the Phase 1 Trial of Ozekibart (INBRX-109) for the Treatment of Colorectal Cancer
PR NewswireJan 21 17:01 ET

Comments

Jaguar8

Yesterday 13:03

🟢 Watchlist, JANUARY 22,2025, Wednesday. NFA

NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
8. With regards ...

Jaguar8

Yesterday 06:02

one complete response (CR), three partial responses (PR), and six cases of stable disease (SD

$Inhibrx Biosciences (INBX.US)$

Jaguar8

Yesterday 06:01

NEWS

$Inhibrx Biosciences (INBX.US)$
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer
Tuesday, 21st January at 5:01 pm
SAN DIEGO, Jan. 21, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced preliminary efficacy and safety data from the Phase 1 trial...